Maus MV - Search Results

1

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.

Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL. Gill S, et al. Among authors: maus mv. Blood Adv. 2022 Nov 8;6(21):5774-5785. doi: 10.1182/bloodadvances.2022007317. Blood Adv. 2022. PMID: 35349631 Free PMC article. Clinical Trial.

2

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH. Maus MV, et al. Nat Biotechnol. 2002 Feb;20(2):143-8. doi: 10.1038/nbt0202-143. Nat Biotechnol. 2002. PMID: 11821859

3

Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation.

Kovacs B, Maus MV, Riley JL, Derimanov GS, Koretzky GA, June CH, Finkel TH. Kovacs B, et al. Among authors: maus mv. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15006-11. doi: 10.1073/pnas.232058599. Epub 2002 Nov 5. Proc Natl Acad Sci U S A. 2002. PMID: 12419850 Free PMC article.

4

A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.

Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. Thomas AK, et al. Among authors: maus mv. Clin Immunol. 2002 Dec;105(3):259-72. doi: 10.1006/clim.2002.5277. Clin Immunol. 2002. PMID: 12498807

5

HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells.

Maus MV, Riley JL, Kwok WW, Nepom GT, June CH. Maus MV, et al. Clin Immunol. 2003 Jan;106(1):16-22. doi: 10.1016/s1521-6616(02)00017-7. Clin Immunol. 2003. PMID: 12584046

6

TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.

Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G, Kaiser LR, Rubin SC, Levine BL, Carroll RG, June CH. Schlienger K, et al. Among authors: maus mv. Clin Cancer Res. 2003 Apr;9(4):1517-27. Clin Cancer Res. 2003. PMID: 12684428

7

Extensive replicative capacity of human central memory T cells.

Maus MV, Kovacs B, Kwok WW, Nepom GT, Schlienger K, Riley JL, Allman D, Finkel TH, June CH. Maus MV, et al. J Immunol. 2004 Jun 1;172(11):6675-83. doi: 10.4049/jimmunol.172.11.6675. J Immunol. 2004. PMID: 15153483

8

Zoom Zoom: racing CARs for multiple myeloma.

Maus MV, June CH. Maus MV, et al. Clin Cancer Res. 2013 Apr 15;19(8):1917-9. doi: 10.1158/1078-0432.CCR-13-0168. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444214 Free PMC article.

9

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Linette GP, et al. Among authors: maus mv. Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14. Blood. 2013. PMID: 23770775 Free PMC article.

10

Immunotherapy with chimeric antigen receptors for multiple myeloma.

Garfall AL, Fraietta JA, Maus MV. Garfall AL, et al. Among authors: maus mv. Discov Med. 2014 Jan;17(91):37-46. Discov Med. 2014. PMID: 24411699 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page